What the FDA labels say about taking them together
Eltrombopag and glyburide
Eltrombopag's FDA label of December 18, 2025 names glyburide in its drug interactions section; the glyburide label PlainMeds reads does not name eltrombopag.
Check it at the source: the eltrombopag FDA label on DailyMed (effective December 18, 2025, Novartis Pharmaceuticals Corporation); the glyburide FDA label on DailyMed (effective July 1, 2021, TEVA Pharmaceuticals USA Inc).
What does the eltrombopag label say about glyburide?
Eltrombopag label, drug interactionsUse caution when concomitantly administering PROMACTA and drugs that are substrates of OATP1B1 (e.g., atorvastatin, bosentan, ezetimibe, fluvastatin, glyburide, olmesartan, pitavastatin, pravastatin, rosuvastatin, repaglinide, rifampin, simvastatin acid, SN-38 [active metabolite of irinotecan], valsartan) or breast cancer resistance protein (BCRP) (e.g., imatinib, irinotecan, lapatinib, methotrexate, mitoxantrone, rosuvastatin, sulfasalazine, topotecan).
Source: FDA drug label (Alvaiz, NDA216774), Teva Pharmaceuticals, Inc., effective January 1, 2026 (SPL set ed51e463-7a03-4858-bbd2-882ce4753d5a), via openFDA
Source: FDA drug label (PROMACTA), Novartis Pharmaceuticals Corporation, effective December 18, 2025 (SPL set 7714a0ed-34bb-46e6-a0a5-b363908b22c2), via openFDA; the full label on DailyMed
What does the glyburide label say about eltrombopag?
Glyburide's label (effective July 1, 2021) does not name eltrombopag in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Glyburide), NDA017532 (Sanofi Aventis Us), as published by TEVA Pharmaceuticals USA Inc, effective July 1, 2021 (SPL set 50d16f1d-c814-4411-8749-62561321ecce), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Eltrombopag | Glyburide | |
|---|---|---|
| Labeled for | Anemia | Type 2 diabetes |
| Boxed warning | Yes | No |
| Pharmacy cost (NADAC) | $25.85 per tablet 50 mg tablet | $0.0643 per tablet 5 mg tablet |
| Shortage now | No current entry | A presentation being discontinued |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once